

Pier Maria Battezzati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7824443/publications.pdf>

Version: 2024-02-01

91
papers

5,550
citations

66234

42
h-index

79541

73
g-index

92
all docs

92
docs citations

92
times ranked

4069
citing authors

#	ARTICLE	IF	CITATIONS
1	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	2.4	30
2	CA.ME.LI.A. An epidemiological study on the prevalence of Cardiovascular, MEtabolic, Llver and Autoimmune diseases in Northern Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1416-1426.	1.1	1
3	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	0.6	27
4	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
5	Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population. <i>International Journal of Cardiology</i> , 2020, 300, 209-213.	0.8	15
6	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	6.1	28
7	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
8	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
9	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	1.8	148
10	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	3.6	55
11	Seroepidemiology of HEV and HAV in two populations with different socio-economic levels and hygienic/sanitary conditions. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 479-485.	1.3	12
12	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. <i>Scientific Reports</i> , 2016, 6, 25906.	1.6	132
13	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
14	ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. <i>Journal of Gastroenterology</i> , 2016, 51, 271-280.	2.3	45
15	Age- and Sex-Dependent Distribution of OGTT-Related Variables in a Population of Cystic Fibrosis Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2963-2971.	1.8	15
16	Role of Lipoylation of the Immunodominant Epitope of Pyruvate Dehydrogenase Complex: Toward a Peptide-Based Diagnostic Assay for Primary Biliary Cirrhosis. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6619-6629.	2.9	7
17	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2014, 46, 363-368.	0.4	11
18	Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 174, 37-42.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Risk of Obstructive Sleep Apnea with Daytime Sleepiness Is Associated with Liver Damage in Non-Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e96349.	1.1	31
20	Response to the letter by Ooi et al.. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 74-75.	0.3	0
21	Insulin secretion, nutritional status and respiratory function in cystic fibrosis patients with normal glucose tolerance. <i>Clinical Nutrition</i> , 2012, 31, 118-123.	2.3	24
22	Acupuncture for paroxysmal and persistent atrial fibrillation: An effective non-pharmacological tool?. <i>World Journal of Cardiology</i> , 2012, 4, 60.	0.5	34
23	Novel Soy Germ Pasta Improves Endothelial Function, Blood Pressure, and Oxidative Stress in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1946-1948.	4.3	47
24	MMP-1 and MMP-3 polymorphism and arrhythmia recurrence after electrical cardioversion in patients with persistent atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 37-42.	0.6	12
25	Efficacy of Acupuncture in Preventing Atrial Fibrillation Recurrences After Electrical Cardioversion. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 241-247.	0.8	77
26	Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. <i>Thorax</i> , 2011, 66, 260-261.	2.7	31
27	Identification of insulin secretory defects and insulin resistance during oral glucose tolerance test in a cohort of cystic fibrosis patients. <i>European Journal of Endocrinology</i> , 2011, 165, 69-76.	1.9	40
28	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 436-442.	3.0	123
29	Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. <i>Digestive and Liver Disease</i> , 2009, 41, e8-e10.	0.4	38
30	Treatment with PEG-Interferon and Ribavirin for Chronic Hepatitis C Increases Neutrophil and Monocyte Chemotaxis. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 847-857.	1.8	11
31	Is autoimmunity a matter of sex?. <i>Autoimmunity Reviews</i> , 2008, 7, 626-630.	2.5	172
32	Primary Biliary Cirrhosis is not an Additional Risk Factor for Bone Loss in Women Receiving Regular Calcium and Vitamin D Supplementation. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 306-311.	1.1	29
33	Clinical features and management of primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3313.	1.4	41
34	Inadequate dietary intake but not renal tubular acidosis is associated with bone demineralization in primary biliary cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 219-227.	1.9	4
35	Spontaneous hypoglycemia in patients with cystic fibrosis. <i>European Journal of Endocrinology</i> , 2007, 156, 369-376.	1.9	49
36	Pasta Naturally Enriched with Isoflavone Aglycons from Soy Germ Reduces Serum Lipids and Improves Markers of Cardiovascular Risk. <i>Journal of Nutrition</i> , 2007, 137, 2270-2278.	1.3	95

#	ARTICLE	IF	CITATIONS
37	Bone disease in primary biliary cirrhosis and renal tubular acidosis: authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1134-1134.	1.9	0
38	X Monosomy in Female Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 84-91.	1.8	48
39	Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. <i>Hepatology</i> , 2006, 43, 1135-1144.	3.6	171
40	Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. <i>Gut</i> , 2006, 55, 1795-1800.	6.1	74
41	Vaccines in the 21st century: the genetic response and the innocent bystander. <i>Autoimmunity Reviews</i> , 2005, 4, 79-81.	2.5	14
42	X Chromosome Monosomy: A Common Mechanism for Autoimmune Diseases. <i>Journal of Immunology</i> , 2005, 175, 575-578.	0.4	180
43	Prognostic value of C-reactive protein in patients with stress induced myocardial ischemia. <i>International Journal of Cardiology</i> , 2005, 98, 313-317.	0.8	8
44	Liver involvement in cystic fibrosis: primary organ damage or innocent bystander?. <i>Journal of Hepatology</i> , 2004, 41, 1041-1044.	1.8	35
45	Frequency of monosomy X in women with primary biliary cirrhosis. <i>Lancet, The</i> , 2004, 363, 533-535.	6.3	252
46	Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: Association with disease severity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1150-1155.	1.4	20
47	Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. <i>Journal of Hepatology</i> , 2003, 38, 499-505.	1.8	14
48	Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 38, 401-406.	1.8	75
49	Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. <i>Gut</i> , 2002, 51, 265-269.	6.1	150
50	Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. <i>Hepatology</i> , 2002, 36, 1374-1382.	3.6	207
51	Presence of fetal DNA in maternal plasma decades after pregnancy. <i>Human Genetics</i> , 2002, 110, 587-591.	1.8	67
52	Presence of fetal DNA in maternal plasma decades after pregnancy: further comments. <i>Human Genetics</i> , 2002, 111, 576-576.	1.8	8
53	Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. <i>Hepatology</i> , 2002, 36, 993-1000.	3.6	80
54	Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. <i>Hepatology</i> , 2002, 36, 1374-1382.	3.6	173

#	ARTICLE	IF	CITATIONS
55	Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2001, 34, 366-372.	1.8	150
56	Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. <i>Journal of Hepatology</i> , 2001, 34, 748-755.	1.8	75
57	Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion. <i>Journal of the American College of Cardiology</i> , 2001, 37, 157-162.	1.2	121
58	Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1427-1434.	1.9	35
59	Blood fetal microchimerism in primary biliary cirrhosis. <i>Clinical and Experimental Immunology</i> , 2000, 122, 418-422.	1.1	67
60	Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. <i>Hepatology</i> , 1999, 29, 320-327.	3.6	75
61	Liver involvement in cystic fibrosis. <i>Journal of Hepatology</i> , 1999, 31, 946-954.	1.8	51
62	Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease. <i>Journal of Hepatology</i> , 1999, 31, 672-677.	1.8	17
63	Complement System Is Not Activated in Primary Biliary Cirrhosis. <i>Clinical Immunology and Immunopathology</i> , 1998, 87, 297-303.	2.1	10
64	Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy. <i>Journal of Medical Virology</i> , 1998, 55, 7-11.	2.5	37
65	Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. <i>Clinical and Experimental Immunology</i> , 1998, 114, 448-454.	1.1	55
66	Liver and Biliary Problems in Cystic Fibrosis. <i>Seminars in Liver Disease</i> , 1998, 18, 227-235.	1.8	111
67	Interferon- α in Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 1998, 128, 956.	2.0	4
68	Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 409-414.	1.9	29
69	Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. <i>Hepatology</i> , 1997, 25, 1090-1095.	3.6	286
70	Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 809-815.	1.1	43
71	Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial. <i>Hepatology</i> , 1996, 23, 1484-1490.	3.6	205
72	Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial. <i>Hepatology</i> , 1996, 23, 1484-1490.	3.6	4

#	ARTICLE	IF	CITATIONS
73	Primary biliary cirrhosis is associated with specific changes in liver IgG-bearing cell subpopulations. <i>Journal of Hepatology</i> , 1995, 22, 545-550.	1.8	10
74	Hepatobiliary Disease in Cystic Fibrosis. <i>Seminars in Liver Disease</i> , 1994, 14, 259-269.	1.8	50
75	Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. <i>Hepatology</i> , 1994, 20, 633-637.	3.6	67
76	Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. <i>Hepatology</i> , 1994, 20, 633-7.	3.6	18
77	Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1993, 17, 332-338.	1.8	66
78	Hepatitis C virus testing in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1992, 15, 207-210.	1.8	8
79	Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. <i>Hepatology</i> , 1992, 16, 924-930.	3.6	127
80	Lack of association between circulating HCV-RNA and anti-HCV positivity in primary biliary cirrhosis. <i>Lancet</i> , The, 1991, 337, 675-676.	6.3	3
81	Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. <i>Hepatology</i> , 1991, 13, 339-344.	3.6	95
82	Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: A study of bile acid metabolism. <i>Hepatology</i> , 1991, 13, 1076-1083.	3.6	24
83	Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. <i>Hepatology</i> , 1991, 14, 1000-1007.	3.6	122
84	Comparison of Effects of Chenodeoxycholic and Ursodeoxycholic Acid and Their Combination on Biliary Lipids in Obese Patients with Gallstones. <i>Scandinavian Journal of Gastroenterology</i> , 1991, 26, 257-262.	0.6	9
85	Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. <i>Hepatology</i> , 1991, 14, 1000-1007.	3.6	12
86	Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. <i>Hepatology</i> , 1991, 13, 339-344.	3.6	11
87	Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. <i>Hepatology</i> , 1991, 14, 1000-7.	3.6	28
88	Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. <i>Gastroenterology</i> , 1990, 98, 1044-1050.	0.6	104
89	Effect of different doses of ursodeoxycholic acid in chronic liver disease. <i>Digestive Diseases and Sciences</i> , 1989, 34, S59-S65.	1.1	72
90	Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: A comparison with ursodeoxycholic acid alone. <i>Gastroenterology</i> , 1989, 96, 222-229.	0.6	134

#	ARTICLE	IF	CITATIONS
91	Ursodeoxycholic acid for chronic liver diseases. Journal of Clinical Gastroenterology, 1988, 10 Suppl 2, S25-31.	1.1	11